Automate Your Wheel Strategy on CRMD
With Tiblio's Option Bot, you can configure your own wheel strategy including CRMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRMD
- Rev/Share 1.2653
- Book/Share 1.7609
- PB 6.65
- Debt/Equity 0.0041
- CurrentRatio 4.2122
- ROIC 0.1255
- MktCap 871565932.0
- FreeCF/Share -0.2089
- PFCF -63.9332
- PE 44.471
- Debt/Assets 0.0032
- DivYield 0
- ROE 0.2257
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 1
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | CRMD | D. Boral Capital | Buy | Hold | -- | -- | June 30, 2025 |
| Initiation | CRMD | H.C. Wainwright | -- | Buy | -- | $20 | June 30, 2025 |
| Initiation | CRMD | Leerink Partners | -- | Outperform | -- | $18 | March 7, 2025 |
| Initiation | CRMD | D. Boral Capital | -- | Buy | -- | $15 | Jan. 13, 2025 |
| Initiation | CRMD | Rodman & Renshaw | -- | Buy | -- | $13 | Aug. 26, 2024 |
News
CorMedix Seems Significantly Undervalued
Published: June 30, 2025 by: Seeking Alpha
Sentiment: Positive
CorMedix offers high upside potential with DefenCath, the only FDA-approved catheter lock solution for CRBSI, and a strong financial position. My DCF model shows a base-case fair value of $26.2 per share, representing 110% upside; the options market also signals bullish sentiment. Key risks include reliance on a single product and high market share uncertainty, so I keep my position size small and avoid options due to illiquidity and high premiums.
Read More
Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Published: June 27, 2025 by: Benzinga
Sentiment: Negative
U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Friday.
Read More
Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
CorMedix inc. Announces Customer Implementation
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY HEIGHTS, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces an update related to its Large Dialysis Organization (LDO) customer and planned implementation in the second half of 2025.
Read More
CorMedix: DefenCath In Exponential Growth Phase With Robust Market Position
Published: June 05, 2025 by: Seeking Alpha
Sentiment: Positive
I am bullish on CorMedix due to its strong financial turnaround, robust revenue growth, and unique market position. DefenCath, the only FDA-approved antimicrobial catheter lock solution in the US, drives exponential revenue and profitability, with high adoption potential. CRMD's competitive edge lies in its first-mover advantage, high efficacy, and significant penetration in the US dialysis market.
Read More
CorMedix: Exceeding Expectations
Published: June 04, 2025 by: Seeking Alpha
Sentiment: Positive
CorMedix and its flagship product DefenCath have significantly outperformed expectations since commercialization, driving strong stock performance in 2025. DefenCath, approved just over a year ago, is proving highly effective in reducing catheter-related bloodstream infections, supporting its 'best of breed' status. Recent Q1 results beat consensus estimates, and the stock has strong analyst support and some recent upwardly revised price targets, reflecting confidence in continued growth.
Read More
Surging Earnings Estimates Signal Upside for CorMedix (CRMD) Stock
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix (CRMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
CorMedix, Inc. (CRMD) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
CorMedix, Inc. (NASDAQ:CRMD ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Dan Ferry – LifeSci Advisors Joe Todisco – Chief Executive Officer Matt David – Executive Vice President and Chief Financial Officer Liz Hurlburt – Executive Vice President, Chief Clinical Strategy and Operations Officer Conference Call Participants Gregory Renza – RBC Capital Roana Ruiz – Leerink Partners Leszek Sulewski – Truist Securities Serge Belanger – Needham & Company Operator Good day and welcome to the CorMedix, Inc. First Quarter 2025 Financial Results Conference Call. All participants will be in listen-only mode.
Read More
CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
CorMedix (CRMD) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to loss of $0.25 per share a year ago.
Read More
CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ.
Read More
CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time.
Read More
Lost Money on CorMedix Inc.(CRMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Published: March 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CorMedix Inc. ("CorMedix Inc.") (NASDAQ:CRMD) concerning possible violations of federal securities laws. Cormedix reported fourth quarter and full year 2024 financial results.
Read More
CorMedix Inc. (CRMD) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
Published: March 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CorMedix Inc. ("CorMedix Inc.") (NASDAQ:CRMD) concerning possible violations of federal securities laws. Cormedix reported fourth quarter and full year 2024 financial results.
Read More
CorMedix Inc. (CRMD) Q4 2024 Earnings Call Transcript
Published: March 25, 2025 by: Seeking Alpha
Sentiment: Neutral
CorMedix Inc. (NASDAQ:CRMD ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Dan Ferry - Managing Director, LifeSci Advisors Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Erin Mistry - Executive Vice President and Chief Commercial Officer Liz Hurlburt - Executive Vice President, Chief Clinical Strategy and Operations Officer Conference Call Participants Roanna Ruiz - Leerink Partners Jason Butler - Citizens JMP Anish Nikhanj - RBC Capital Markets Jeevan Larson - Truist Securities John Todaro - Needham & Company Operator Good day and welcome to the CorMedix …
Read More
About CorMedix Inc. (CRMD)
- IPO Date 2010-05-13
- Website https://www.cormedix.com
- Industry Biotechnology
- CEO Joseph Todisco MBA
- Employees 64